Skip to content

Study · Non-randomized trial · n = 19 · 2011

10 results

Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.

Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, Sainsbury A, Steinbeck K, Campbell LV, Viardot A

The Journal of clinical endocrinology and metabolism1 Jun 2011Cited by 44 (Europe PMC)

PMID21632815 (opens in a new tab)DOI10.1210/jc.2011-0038 (opens in a new tab)PepBankPUB-21632815
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with Prader-Willi syndrome and obese controls, exenatide increased satiety compared with placebo.

    In plain wordsIn adults with Prader-Willi syndrome and obese controls, exenatide increased satiety compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSatiety
    Study

    n = 19

    Comparator
    placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    In both groups, exenatide increased satiety and lowered glucose and insulin levels but increased insulin secretion rate.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with Prader-Willi syndrome and obese controls, exenatide lowered glucose compared with placebo.

    In plain wordsIn adults with Prader-Willi syndrome and obese controls, exenatide lowered glucose compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlucose levels
    Study

    n = 19

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    In both groups, exenatide increased satiety and lowered glucose and insulin levels but increased insulin secretion rate.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults with Prader-Willi syndrome and obese controls, exenatide lowered insulin levels compared with placebo.

    In plain wordsIn adults with Prader-Willi syndrome and obese controls, exenatide lowered insulin levels compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin levels
    Study

    n = 19

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    In both groups, exenatide increased satiety and lowered glucose and insulin levels but increased insulin secretion rate.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with Prader-Willi syndrome and obese controls, exenatide increased insulin secretion rate compared with placebo.

    In plain wordsIn adults with Prader-Willi syndrome and obese controls, exenatide increased insulin secretion rate compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin secretion rate
    Study

    n = 19

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    In both groups, exenatide increased satiety and lowered glucose and insulin levels but increased insulin secretion rate.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.
  5. 05HumanNon-randomized trialSafety outcome

    In obese controls, side effects were common after exenatide.

    In plain wordsIn obese controls, side effects were common after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSide effects in obese controls
    Study

    n = 11

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Side effects were absent in PWS but common in OBESE patients.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.
  6. 06HumanNon-randomized trialSafety outcome

    In adults with Prader-Willi syndrome, side effects were absent after exenatide.

    In plain wordsIn adults with Prader-Willi syndrome, no side effects occurred after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSide effects in Prader-Willi syndrome
    Study

    n = 8

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Side effects were absent in PWS but common in OBESE patients.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.
  7. 07HumanNon-randomized trialEfficacy outcome

    In the Prader-Willi syndrome and obesity meal study, exenatide decreased total PYY compared with placebo.

    In plain wordsIn the Prader-Willi syndrome and obesity meal study, exenatide decreased total PYY compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTotal PYY
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Exenatide decreased PYY (total) and glucagon-like peptide-1, whereas ghrelin remained unchanged.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.
  8. 08HumanNon-randomized trialEfficacy outcome

    In the Prader-Willi syndrome and obesity meal study, exenatide decreased GLP-1 compared with placebo.

    In plain wordsIn the Prader-Willi syndrome and obesity meal study, exenatide decreased GLP-1 compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGLP-1
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Exenatide decreased PYY (total) and glucagon-like peptide-1, whereas ghrelin remained unchanged.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.
  9. 09HumanNon-randomized trialEfficacy outcome

    In the Prader-Willi syndrome and obesity meal study, exenatide did not change ghrelin compared with placebo.

    In plain wordsIn the Prader-Willi syndrome and obesity meal study, exenatide did not change ghrelin compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGhrelin
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Exenatide decreased PYY (total) and glucagon-like peptide-1, whereas ghrelin remained unchanged.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.
  10. 10HumanNon-randomized trialEfficacy outcome

    In adults with Prader-Willi syndrome and obese controls, exenatide did not change energy expenditure compared with placebo.

    In plain wordsIn adults with Prader-Willi syndrome and obese controls, exenatide did not change energy expenditure compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeEnergy expenditure
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    10 μg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Energy expenditure was unchanged by exenatide.
    1 context sentence
    Summary · context
    Eight PWS and 11 OBESE patients underwent standardized meal studies after a single sc injection of 10 μg exenatide or placebo in a single-blinded, crossover design.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 4NCT01542242

Liraglutide Use in Prader-Willi Syndrome

Vancouver General Hospitaln = 1Feb 2012 to Mar 2013

Diabetes Mellitus Type 2 · Prader Willi Syndrome

Trial pageClinicalTrials.govUpdated 9 Dec 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.